1. Hydroxyurea Initiation Among Children With Sickle Cell Anemia
- Author
-
Sarah L. Reeves, Jennifer P. Gondhi, Lynda D. Lisabeth, Hannah K. Jary, Jean L. Raphael, and Kevin J. Dombkowski
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Demographics ,Anemia, Sickle Cell ,Logistic regression ,Article ,03 medical and health sciences ,0302 clinical medicine ,Antisickling Agents ,Health care ,medicine ,Humans ,Hydroxyurea ,Medical prescription ,Child ,Medicaid ,business.industry ,Infant ,Emergency department ,Patient Acceptance of Health Care ,medicine.disease ,United States ,Sickle cell anemia ,Administrative claims ,Hospitalization ,Child, Preschool ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Female ,business ,030215 immunology - Abstract
This study assesses characteristics of children with sickle cell anemia associated with hydroxyurea initiation. Medicaid administrative claims from 6 states (2005-2012) were used to identify children with sickle cell anemia enrolled in Medicaid for ≥2 years. Hydroxyurea use was defined as >30 days’ supply of filled prescriptions. Children were classified as initiators (no use in year 1; use in year 2) or nonusers (no use in either year). Logistic regression was used to estimate associations between initiation, health care encounters, and demographics. A total of 4435 children were enrolled for 2 years during the study period; 885 (20.0%) initiators and 3080 (69.4%) nonusers. Children had an annual mean of 2.0 sickle cell disease–related inpatient admissions (SD = 2.2), 8.2 sickle cell disease–related outpatient visits (SD = 7.2), and 3.6 emergency department visits (SD = 3.5). The odds of initiating hydroxyurea increased with increasing health care utilization, age, and calendar year (all P values
- Published
- 2019
- Full Text
- View/download PDF